Myriad Genetics EndoPredict Test

Myriad Genetics has launched the EndoPredict test, a second-generation test for assessing the 10-year risk of disease recurrence in patients with ER+ HER2- early-stage breast cancer. The test includes proliferation-related genes and hormone receptor-related genes to provide clinicians with an accurate assessment of early and late risk recurrence, the company said. It uses this information to definitively classify patients as low or high risk, which helps clinicians make therapy decisions going forward.